Literature DB >> 21140268

Serum levels of angiopoietin-1 in patients with pulmonary hypertension due to mitral stenosis.

Hekim Karapınar1, Ozlem Esen, Yunus Emiroğlu, Mustafa Akçakoyun, Selçuk Pala, Ramazan Kargın, Akın Izgi, Cevat Kirma, Ali Metin Esen.   

Abstract

The molecular basis and pathophysiology of pulmonary hypertension (PH) are rapidly evolving areas. Recently discovered angiopoietins (Ang) constitute a family of growth factors, and whether they play a causal or protective role in pulmonary hypertension has not been fully elucidated. Since left heart disease probably represents the most frequent cause of PH, we sought to determine whether there was a relationship between serum Ang-1 levels and pulmonary hypertension caused by mitral stenosis (MS). The study population was composed of 49 patients with isolated MS. These patients were then divided into group 1 [31 patients with severe MS: mitral valve area (MVA) ≤1.1 cm(2)] and group 2 (18 patients with mild-moderate MS: MVA 1.2-2.0 cm(2)). Twenty-one healthy volunteers comprised the control group (group 3). All of the subjects underwent complete transthoracic echocardiography with determination of systolic pulmonary artery pressure (PAPs). Ang-1 levels were determined in serum. Serum levels of Ang-1 were significantly higher in the control group compared to patients with severe (group 1) and mild-moderate (group 2) MS (p < 0.001). Ang-1 levels were found to have moderate inverse correlation with PAPs and left atrial (LA) diameter (r: -0.620, p < 0.001 and r: -0.489, p < 0.001, respectively). The AUC for the ROC curve for predicting PAPs <50 mmHg by serum Ang-1 level was 0.824 (95% CI 0.722-0.926, p < 0.001). A serum level of Ang-1 above 34,656 pg/ml has 74% sensitivity and 80% specificity for predicting that PH is not severe (PAPs <50 mmHg). In conclusion, the findings of this study are distinctive in the sense that they clearly demonstrate a negative correlation between serum Ang-1 levels and the degree of PH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21140268     DOI: 10.1007/s00380-010-0092-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  22 in total

Review 1.  Pulmonary hypertension associated with left-sided heart disease.

Authors:  Ronald J Oudiz
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

2.  Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues.

Authors:  A L Wong; Z A Haroon; S Werner; M W Dewhirst; C S Greenberg; K G Peters
Journal:  Circ Res       Date:  1997-10       Impact factor: 17.367

3.  Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava.

Authors:  B J Kircher; R B Himelman; N B Schiller
Journal:  Am J Cardiol       Date:  1990-08-15       Impact factor: 2.778

4.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation.

Authors:  T N Sato; Y Tozawa; U Deutsch; K Wolburg-Buchholz; Y Fujiwara; M Gendron-Maguire; T Gridley; H Wolburg; W Risau; Y Qin
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

5.  Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy.

Authors:  S V Abramson; J F Burke; J J Kelly; J G Kitchen; M J Dougherty; D F Yih; F C McGeehin; J W Shuck; T P Phiambolis
Journal:  Ann Intern Med       Date:  1992-06-01       Impact factor: 25.391

6.  Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats.

Authors:  K Abdulmalek; F Ashur; N Ezer; F Ye; S Magder; S N Hussain
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-09       Impact factor: 5.464

7.  Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.

Authors:  S Davis; T H Aldrich; P F Jones; A Acheson; D L Compton; V Jain; T E Ryan; J Bruno; C Radziejewski; P C Maisonpierre; G D Yancopoulos
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

8.  Downregulation of angiopoietin-1 and Tie2 in chronic hypoxic pulmonary hypertension.

Authors:  Akihito Yamamoto; Hideki Takahashi; Yuko Kojima; Yasunari Tsuda; Yoshiteru Morio; Masashi Muramatsu; Yoshinosuke Fukuchi
Journal:  Respiration       Date:  2007-12-10       Impact factor: 3.580

9.  Protective role of angiopoietin-1 in experimental pulmonary hypertension.

Authors:  Yidan D Zhao; Andrew I M Campbell; Malcolm Robb; Douglas Ng; Duncan J Stewart
Journal:  Circ Res       Date:  2003-04-10       Impact factor: 17.367

10.  The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting.

Authors:  Jianguang Qi; Junbao Du; Xiuying Tang; Jian Li; Bing Wei; Chaoshu Tang
Journal:  Heart Vessels       Date:  2004-03       Impact factor: 2.037

View more
  4 in total

Review 1.  Pulmonary hypertension in obstructive sleep apnea: is it clinically significant? A critical analysis of the association and pathophysiology.

Authors:  Cyrus Kholdani; Wassim H Fares; Vahid Mohsenin
Journal:  Pulm Circ       Date:  2015-06       Impact factor: 3.017

2.  Clinical significance of Angiopoietin-1 in Behcet's disease patients with vascular involvement.

Authors:  Iman H Bassyouni; Mohammed Sharaf; Iman E Wali; Hossam M Mansour
Journal:  Heart Vessels       Date:  2015-05-12       Impact factor: 2.037

Review 3.  A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?

Authors:  Gerald Maarman; Sandrine Lecour; Ghazwan Butrous; Friedrich Thienemann; Karen Sliwa
Journal:  Pulm Circ       Date:  2013-12       Impact factor: 3.017

4.  Vascular disruption and the role of angiogenic proteins after spinal cord injury.

Authors:  Michelle T L Ng; Anthea T Stammers; Brian K Kwon
Journal:  Transl Stroke Res       Date:  2011-10-13       Impact factor: 6.829

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.